Abstract
Findings regarding humoral and cellular response are consistent with previous reports, indicating that while certain Multiple Sclerosis (MS) treatments impair antibody production following adenovirus-based vaccination, cellular immunity often remains intact.
Introduction
While extensive data exists regarding mRNA-based COVID-19 vaccines (like Pfizer or Moderna), a significant knowledge gap remains concerning adenovirus-based platforms such as Sputnik V and AstraZeneca (AZD1222). These vaccines were cornerstones of the pandemic response in Latin America. This study investigates how Disease-Modifying Therapies (DMTs) used in MS affect the immune response to these specific vaccine vectors, particularly against emerging variants like Omicron.
Methods
Researchers conducted a prospective, longitudinal study in Argentina involving 101 patients with MS (pwMS) and 28 healthy controls (HC). The pwMS were grouped by their specific DMT: fingolimod, dimethyl fumarate (DMF), cladribine, or anti-CD20 therapies (ocrelizumab/rituximab).
Key technical approaches included measuring IgG antibodies against the SARS-CoV-2 spike protein (COVIDAR platform), neutralization assays against the Wuhan and Omicron variants, and flow cytometry to analyze T-cell activation (CD4+ and CD8+ cells) after stimulating peripheral blood mononuclear cells with viral peptides.
Key Results
The study revealed that treatment type significantly influences seroconversion rates. After two doses, 100% of patients on DMF and Cladribine produced antibodies, compared to only 57.8% on fingolimod and a mere 26.4% on anti-CD20 therapies.
Multivariate regression identified anti-CD20 ($p=0.017$) and fingolimod ($p=0.023$) as independent factors associated with low antibody response. Furthermore, for patients on anti-CD20, antibody titers were higher when the interval between the drug infusion and vaccination was longer ($r=0.49, p=0.03$).
Discussion: The T-Cell Safety Net and Booster Efficacy
Perhaps the most encouraging finding was the preservation of cellular immunity. Patients on anti-CD20 therapies—who often failed to produce detectable antibodies—still generated robust CD8+ T-cell responses comparable to healthy controls. This suggests that even if the antibody response is impaired, the body's cellular "internal security" can still recognize and fight the virus.
Additionally, the third vaccine dose proved vital. For some previous non-responders (particularly those on fingolimod), the third dose triggered seroconversion. While neutralization capacity against Omicron was lower than against the original Wuhan strain across all groups, the third dose significantly narrowed this gap, reinforcing the necessity of boosters for immunocompromised populations.
Limitations and Future Work
The authors acknowledge limitations including a relatively small sample size in some DMT subgroups and the lack of baseline antibody data prior to the first vaccine dose. Future research should focus on whether adjusting the timing of DMT infusions can further optimize the window for vaccination without increasing the risk of MS relapses.
Summary updated